Effects of Statins on Cardiorenal Syndrome. (26th June 2012)

• Record Type: Journal Article
• Authors: Yagi, Shusuke; Aihara, Ken-ichi; Ikeda, Yasumasa; Akaike, Masashi; Sata, Masataka; Matsumoto, Toshio
• Other Names: Bishop-Bailey David Academic Editor.
• Is Part Of: International journal of vascular medicine. Volume 2012(2012)
• Publication Date: 2012-06-26
• Subjects: Blood-vessels -- Diseases -- Periodicals; 616.13005
• DOI: 10.1155/2012/162545
• Languages: English
• ISSNs: 2090-2824

Abstract

Abstract : Cardiovascular disease and renal disease have a close relationship that forms a vicious cycle as a cardiorenal syndrome (CRS). Oxidative stress, endothelial dysfunction, and vascular inflammation could be therapeutic targets when the renin-angiotensin-aldosterone system is activated by accumulation of conventional cardiovascular risk factors; however, a strategy for management of CRS has not been established yet. Statins, HMG-CoA reductase inhibitors, have not only cholesterol-lowering effects but also pleiotropic effects on cardiovascular systems, including anti-inflammatory and antioxidant effects and improvement of nitric oxide bioavailability. Since recent studies have indicated that statins have beneficial effects on chronic kidney disease and heart failure as well as coronary artery disease in cholesterol-lowering-dependent/independent manners, treatment with statins might be a successful strategy for preventing deterioration of CRS.